ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Ponatinib Triggers Thrombosis via TNF Signaling 09/16/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded September 16, 2025. This episode summarizes 5 key cardiology studies on topics like Abl-tyrosine kinase inhibitor and ponatinib. Key takeaway: Ponatinib Triggers Thrombosis via TNF Signaling.
Article Links:
Article 1: Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation. (Journal of the American College of Cardiology)
Article 2: Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease. (Journal of the American College of Cardiology)
Article 3: Effect of ECMO Flow Variations on Pulmonary Capillary Wedge Pressure in Patients With Cardiogenic Shock. (Journal of the American College of Cardiology)
Article 4: TBX5 and CHD4 Coordinately Activate Atrial Cardiomyocyte Genes to Maintain Cardiac Rhythm Homeostasis. (Circulation)
Article 5: Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/ponatinib-triggers-thrombosis-via-tnf-signaling-09-16-25/
Featured Articles
Article 1: Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40930617
Summary: This study, emulating a target trial, compared statin initiation versus non-initiation in adults with type 1 diabetes mellitus (T1DM) using United Kingdom primary care data. The findings suggest that statin initiation was associated with a lower risk of cardiovascular disease and all-cause mortality in this population, supporting the consideration of statins for primary prevention in adults with type 1 diabetes mellitus. These benefits need to be carefully weighed against the potential for adverse effects within individual patient risk profiles.
Article 2: Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40930615
Summary: This study examined angina trajectories following invasive versus conservative strategies for chronic coronary disease using data from the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial. Results showed that while an invasive strategy initially improved angina symptoms, many patients experienced fluctuating symptoms regardless of treatment arm, suggesting that angina management requires ongoing attention beyond the initial treatment strategy. Individual angina patterns highlight the need for personalized and continuous assessment in patients with chronic coronary disease.
Article 3: Effect of ECMO Flow Variations on Pulmonary Capillary Wedge Pressure in Patients With Cardiogenic Shock.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40930613
Summary: This study investigated the impact of incremental femoro-femoral venoarterial extracorporeal membrane oxygenation (VA-ECMO) flow variations on pulmonary capillary wedge pressure, hemodynamic parameters, and echocardiographic parameters in patients with cardiogenic shock. The results demonstrated that increasing extracorporeal membrane oxygenation flow did not significantly increase pulmonary capillary wedge pressure, suggesting that concerns about flow-induced pulmonary edema may be less warranted than previously thought, supporting the optimization of extracorporeal membrane oxygenation flow to achieve adequate systemic perfusion in cardiogenic shock. Hemodynamic management should be based on comprehensive assessment to optimize patient care.
Article 4: TBX5 and CHD4 Coordinately Activate Atrial Cardiomyocyte Genes to Maintain Cardiac Rhythm Homeostasis.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40799140
Summary: This study elucidates the role of T-box 5 (TBX5) and chromodomain helicase DNA-binding protein 4 (CHD4) in maintaining atrial rhythm homeostasis. It found that TBX5 interacts with CHD4 to regulate atrial cardiomyocyte enhancer accessibility and transcriptional identity, critical for preventing atrial fibrillation. These findings reveal potential therapeutic targets for atrial fibrillation by modulating TBX5 and CHD4 activity to restore normal atrial rhythm.
Article 5: Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40762051
Summary: This research investigated the mechanisms behind ponatinib-induced thrombosis compared to the newer Abl-tyrosine kinase inhibitor asciminib. The study demonstrated that ponatinib, but not asciminib, activates platelets, leukocytes, and endothelial cell tumor necrosis factor signaling, leading to atherosclerotic plaque inflammation, myocardial infarction, and stroke. This clarifies the distinct cardiovascular risks associated with different Abl-tyrosine kinase inhibitors, suggesting asciminib as a safer alternative regarding thrombotic events.
Transcript
Today’s date is September 16, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation. This study, emulating a target trial, compared statin initiation versus non-initiation in adults with type 1 diabetes mellitus (T1DM) using United Kingdom primary care data. The findings suggest that statin initiation was associated with a lower risk of cardiovascular disease and all-cause mortality in this population, supporting the consideration of statins for primary prevention in adults with type 1 diabetes mellitus. These benefits need to be carefully weighed against the potential for adverse effects within individual patient risk profiles.
Article number two. Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease. This study examined angina trajectories following invasive versus conservative strategies for chronic coronary disease using data from the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial. Results showed that while an invasive strategy initially improved angina symptoms, many patients experienced fluctuating symptoms regardless of treatment arm, suggesting that angina management requires ongoing attention beyond the initial treatment strategy. Individual angina patterns highlight the need for personalized and continuous assessment in patients with chronic coronary disease.
Article number three. Effect of ECMO Flow Variations on Pulmonary Capillary Wedge Pressure in Patients With Cardiogenic Shock. This study investigated the impact of incremental femoro-femoral venoarterial extracorporeal membrane oxygenation (VA-ECMO) flow variations on pulmonary capillary wedge pressure, hemodynamic parameters, and echocardiographic parameters in patients with cardiogenic shock. The results demonstrated that increasing extracorporeal membrane oxygenation flow did not significantly increase pulmonary capillary wedge pressure, suggesting that concerns about flow-induced pulmonary edema may be less warranted than previously thought, supporting the optimization of extracorporeal membrane oxygenation flow to achieve adequate systemic perfusion in cardiogenic shock. Hemodynamic management should be based on comprehensive assessment to optimize patient care.
Article number four. TBX5 and CHD4 Coordinately Activate Atrial Cardiomyocyte Genes to Maintain Cardiac Rhythm Homeostasis. This study elucidates the role of T-box 5 (TBX5) and chromodomain helicase DNA-binding protein 4 (CHD4) in maintaining atrial rhythm homeostasis. It found that TBX5 interacts with CHD4 to regulate atrial cardiomyocyte enhancer accessibility and transcriptional identity, critical for preventing atrial fibrillation. These findings reveal potential therapeutic targets for atrial fibrillation by modulating TBX5 and CHD4 activity to restore normal atrial rhythm.
Article number five. Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke. This research investigated the mechanisms behind ponatinib-induced thrombosis compared to the newer Abl-tyrosine kinase inhibitor asciminib. The study demonstrated that ponatinib, but not asciminib, activates platelets, leukocytes, and endothelial cell tumor necrosis factor signaling, leading to atherosclerotic plaque inflammation, myocardial infarction, and stroke. This clarifies the distinct cardiovascular risks associated with different Abl-tyrosine kinase inhibitors, suggesting asciminib as a safer alternative regarding thrombotic events.
Thank you for listening. Don’t forget to subscribe.
Keywords
Abl-tyrosine kinase inhibitor, ponatinib, T-box 5, echocardiography, pulmonary capillary wedge pressure, cardiovascular disease, atrial cardiomyocyte, atrial fibrillation, hemodynamics, asciminib, angina, myocardial infarction, all-cause mortality, stroke, primary prevention, type 1 diabetes mellitus, statins, chronic coronary disease, extracorporeal membrane oxygenation, cardiogenic shock, conservative strategy, chromodomain helicase DNA-binding protein 4, invasive strategy, International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA), cardiac rhythm.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Ponatinib Triggers Thrombosis via TNF Signaling 09/16/25 first appeared on Cardiology Today.
Article Links:
Article 1: Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation. (Journal of the American College of Cardiology)
Article 2: Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease. (Journal of the American College of Cardiology)
Article 3: Effect of ECMO Flow Variations on Pulmonary Capillary Wedge Pressure in Patients With Cardiogenic Shock. (Journal of the American College of Cardiology)
Article 4: TBX5 and CHD4 Coordinately Activate Atrial Cardiomyocyte Genes to Maintain Cardiac Rhythm Homeostasis. (Circulation)
Article 5: Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/ponatinib-triggers-thrombosis-via-tnf-signaling-09-16-25/
Featured Articles
Article 1: Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40930617
Summary: This study, emulating a target trial, compared statin initiation versus non-initiation in adults with type 1 diabetes mellitus (T1DM) using United Kingdom primary care data. The findings suggest that statin initiation was associated with a lower risk of cardiovascular disease and all-cause mortality in this population, supporting the consideration of statins for primary prevention in adults with type 1 diabetes mellitus. These benefits need to be carefully weighed against the potential for adverse effects within individual patient risk profiles.
Article 2: Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40930615
Summary: This study examined angina trajectories following invasive versus conservative strategies for chronic coronary disease using data from the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial. Results showed that while an invasive strategy initially improved angina symptoms, many patients experienced fluctuating symptoms regardless of treatment arm, suggesting that angina management requires ongoing attention beyond the initial treatment strategy. Individual angina patterns highlight the need for personalized and continuous assessment in patients with chronic coronary disease.
Article 3: Effect of ECMO Flow Variations on Pulmonary Capillary Wedge Pressure in Patients With Cardiogenic Shock.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40930613
Summary: This study investigated the impact of incremental femoro-femoral venoarterial extracorporeal membrane oxygenation (VA-ECMO) flow variations on pulmonary capillary wedge pressure, hemodynamic parameters, and echocardiographic parameters in patients with cardiogenic shock. The results demonstrated that increasing extracorporeal membrane oxygenation flow did not significantly increase pulmonary capillary wedge pressure, suggesting that concerns about flow-induced pulmonary edema may be less warranted than previously thought, supporting the optimization of extracorporeal membrane oxygenation flow to achieve adequate systemic perfusion in cardiogenic shock. Hemodynamic management should be based on comprehensive assessment to optimize patient care.
Article 4: TBX5 and CHD4 Coordinately Activate Atrial Cardiomyocyte Genes to Maintain Cardiac Rhythm Homeostasis.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40799140
Summary: This study elucidates the role of T-box 5 (TBX5) and chromodomain helicase DNA-binding protein 4 (CHD4) in maintaining atrial rhythm homeostasis. It found that TBX5 interacts with CHD4 to regulate atrial cardiomyocyte enhancer accessibility and transcriptional identity, critical for preventing atrial fibrillation. These findings reveal potential therapeutic targets for atrial fibrillation by modulating TBX5 and CHD4 activity to restore normal atrial rhythm.
Article 5: Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40762051
Summary: This research investigated the mechanisms behind ponatinib-induced thrombosis compared to the newer Abl-tyrosine kinase inhibitor asciminib. The study demonstrated that ponatinib, but not asciminib, activates platelets, leukocytes, and endothelial cell tumor necrosis factor signaling, leading to atherosclerotic plaque inflammation, myocardial infarction, and stroke. This clarifies the distinct cardiovascular risks associated with different Abl-tyrosine kinase inhibitors, suggesting asciminib as a safer alternative regarding thrombotic events.
Transcript
Today’s date is September 16, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation. This study, emulating a target trial, compared statin initiation versus non-initiation in adults with type 1 diabetes mellitus (T1DM) using United Kingdom primary care data. The findings suggest that statin initiation was associated with a lower risk of cardiovascular disease and all-cause mortality in this population, supporting the consideration of statins for primary prevention in adults with type 1 diabetes mellitus. These benefits need to be carefully weighed against the potential for adverse effects within individual patient risk profiles.
Article number two. Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease. This study examined angina trajectories following invasive versus conservative strategies for chronic coronary disease using data from the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial. Results showed that while an invasive strategy initially improved angina symptoms, many patients experienced fluctuating symptoms regardless of treatment arm, suggesting that angina management requires ongoing attention beyond the initial treatment strategy. Individual angina patterns highlight the need for personalized and continuous assessment in patients with chronic coronary disease.
Article number three. Effect of ECMO Flow Variations on Pulmonary Capillary Wedge Pressure in Patients With Cardiogenic Shock. This study investigated the impact of incremental femoro-femoral venoarterial extracorporeal membrane oxygenation (VA-ECMO) flow variations on pulmonary capillary wedge pressure, hemodynamic parameters, and echocardiographic parameters in patients with cardiogenic shock. The results demonstrated that increasing extracorporeal membrane oxygenation flow did not significantly increase pulmonary capillary wedge pressure, suggesting that concerns about flow-induced pulmonary edema may be less warranted than previously thought, supporting the optimization of extracorporeal membrane oxygenation flow to achieve adequate systemic perfusion in cardiogenic shock. Hemodynamic management should be based on comprehensive assessment to optimize patient care.
Article number four. TBX5 and CHD4 Coordinately Activate Atrial Cardiomyocyte Genes to Maintain Cardiac Rhythm Homeostasis. This study elucidates the role of T-box 5 (TBX5) and chromodomain helicase DNA-binding protein 4 (CHD4) in maintaining atrial rhythm homeostasis. It found that TBX5 interacts with CHD4 to regulate atrial cardiomyocyte enhancer accessibility and transcriptional identity, critical for preventing atrial fibrillation. These findings reveal potential therapeutic targets for atrial fibrillation by modulating TBX5 and CHD4 activity to restore normal atrial rhythm.
Article number five. Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke. This research investigated the mechanisms behind ponatinib-induced thrombosis compared to the newer Abl-tyrosine kinase inhibitor asciminib. The study demonstrated that ponatinib, but not asciminib, activates platelets, leukocytes, and endothelial cell tumor necrosis factor signaling, leading to atherosclerotic plaque inflammation, myocardial infarction, and stroke. This clarifies the distinct cardiovascular risks associated with different Abl-tyrosine kinase inhibitors, suggesting asciminib as a safer alternative regarding thrombotic events.
Thank you for listening. Don’t forget to subscribe.
Keywords
Abl-tyrosine kinase inhibitor, ponatinib, T-box 5, echocardiography, pulmonary capillary wedge pressure, cardiovascular disease, atrial cardiomyocyte, atrial fibrillation, hemodynamics, asciminib, angina, myocardial infarction, all-cause mortality, stroke, primary prevention, type 1 diabetes mellitus, statins, chronic coronary disease, extracorporeal membrane oxygenation, cardiogenic shock, conservative strategy, chromodomain helicase DNA-binding protein 4, invasive strategy, International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA), cardiac rhythm.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Ponatinib Triggers Thrombosis via TNF Signaling 09/16/25 first appeared on Cardiology Today.
More episodes of the podcast Cardiology Today
CRISPR-Cas9 Gene Editing for Lipids 11/11/25
11/11/2025
In God we trust